Intelligent hydrogels for the oral delivery of chemotherapeutics

Expert Opinion on Drug Delivery

Volumn 2, Issue 6, 2005, Pages 1003-1013

  Bromberg, Lev ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Chemotherapeutics drugs; Micelles; Microgels; Oral administration; Pluronic polyethers; Poly(acrylic acid); Site specific delivery

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOMER; CARBON; COPOLYMER; CREMOPHOR; DOXORUBICIN; EXCIPIENT; FLUOROURACIL; IRINOTECAN; MEGESTROL ACETATE; NAVELBINE; PACLITAXEL; POLOXAMER; POLYACRYLIC ACID; SURFACTANT; THIOL; THIOMER; TOPOTECAN; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

CARDIOTOXICITY; CHEMICAL BOND; CROSS LINKING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; ERYTHROCYTE AGGREGATION; EXCIPIENT COMPATIBILITY; HUMAN; HYDROGEL; HYPERLIPIDEMIA; MACROMOLECULE; MALIGNANT NEOPLASTIC DISEASE; MICELLE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG CARRIERS; DRUG STABILITY; HUMANS; HYDROGELS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MICELLES; PARTICLE SIZE; POLOXAMER; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 28244447414     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.6.1003     Document Type: Review

References (50)

1. FENG SS, CHIEN S: Chemotherapeutic engineering application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. (2003) 58:4087-4114.
2. AJANI J A, TAKIUCHI H: Recent developments in oral chemotherapy options for gastric carcinoma. Drugs (1999) 58:85-90.
3. DEMARIO MD, RATAIN MJ: Oral chemotherapy rationale and future directions. J. Clin. Oncol. (1999) 16(7):2557-2567.
4. BOTTOMLEY A: The cancer patient and quality of life. Oncologist (2002) 7:120-125.
5. BLANCHETTE J, KAVIMANDAN N, PEPPAS NA: Principles of transmucosal delivery of therapeutic agents. Biomed. Pharmacother. (2004) 58(3):142-151.
6. LORENCE A, NESSLER CL: Camptothecin, over four decades of surprising findings. Phytochemistry (2004) 65(20):2735-2749.
7. MURPHY BA: Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin. Pharmacother. (2005) 6(1):85-92.
8. BERAN M, O'BRIEN S, THOMAS DA et al.: Phase I Study of oral topotecan in hematological malignancies. Clin. Cancer Res. (2003) 9(11):4084-4091.
9. SCHELLENS JH, CREEMERS GJ, BEIJNEN JH et al.: Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer (1996) 73(10):1268-1271.
10. VON PAWEL J, GATZEMEIER U, PUJOL JL et al.: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer J. Clin. Oncol. (2001) 19:1743-1749.
11. GELDERBLOM H, VERWEIJ J, NOOTER K, SPARREBOOM A: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer (2001) 37(13):1590-8159.
12. MALINGRÉ MM, SCHELLENS JH, VAN TELLINGEN O et al.: The cosolvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br. J. Cancer (2001) 85(10):1472-1477.
13. DIAZ R, SEGURA A, APARICIO J, CALDERERO V, GUERRERO A, PELLIN L: Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. J. Chemother. (2004) 16(6):599-603.
14. SCHILSKY RL, LEVIN J, WEST WH et al.: Randomized, open-label, Phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J. Clin. Oncol. (2002) 20(6):1519-1526.
15. BAKER SD: Pharmacology of fluorinated pyrimidines: eniluracil. Invest. New Drugs (2000) 18(4):373-381.
16. NUKATSUKA M, FUJIOKA A, NAKAGAWA F et al.: Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthoropically implanted human breast cancer model. Int. J. Oncol. (2004) 25(6):1531-1536.
17. KANARD A, JATOI A, CASTILLO R et al.: Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a Phase II trial of efficacy and toxicity. Lung Cancer (2004) 43(3):345-353.
18. GRIDELLI C, MANEGOLD C, MALI P et al.: Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre Phase II trial. Eur. J. Cancer (2004) 40(16):2424-2431.
19. ROGERS JA, ANDERSON KE: The potential of liposomes in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (1998) 15(5):421-480.
20. YIN WIN K, FENG SS: Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 26(15):2713-2722.
21. BLANCHETTE J, PEPPAS NA: Cellular evaluation of oral chemotherapy carriers. J. Biomed. Mater. Res. Part A (2005) 72A(4):381-388.
22. BLANCHETTE J, PEPPAS NA: Oral chemotherapeutic delivery: design and cellular response. Ann. Biomed. Eng. (2005) 33(2):142-149.
23. BROMBERG L: Intelligent polyelectrolytes and gels in oral drug delivery Curr. Pharm. Biotechnol. (2003) 4(5):339-349.
24. HAEBERLIN B, FRIEND DR: In: Oral Colon-Specific Drug Delivery. DR Friend (Ed.), CRC Press, Boca Raton, FL, USA (1992):1-44.
25. CHOURASIA MK, JAIN SK: Design and development of multiparticulate system for targeted drug delivery to colon. Drug Deliv. (2004) 11(3):201-207.
26. PEPPAS NA, WOOD KM, BLANCHETTE JO: Hydrogels for oral delivery of therapeutic proteins. Expert Opin. Biol. Ther. (2004) 4(6):881-887.
27. GABIZON A, SHMEEDA H, BARENHOLZ Y: Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. (2003) 42(5):419-436.
28. BROMBERG L: Hydrophobically modified polyelectrolytes and polyelectrolyte block-copolymers. In: Handbook of Surfaces and Interfaces of Materials (Volume 4). Solid Thin Films and Layers. HS Nalwa (Ed.), Academic Press, San Diego, CA, USA (2001):369-404.
29. BROMBERG L: Hydrophobically modified polyelectrolytes and polyelectrolyte block-copolymers for biomedical applications. (Chapter 51). In: Handbook of Polyelectrolytes and Their Applications. SK Tripathy, J Kumar, HS Nalwa (Eds), American Scientific Publishers, Los Angeles, CA, USA (2002):23-46.
30. BROMBERG L, TEMCHENKO M, ALAKHOV V, HATTON TA: Bioadhesive properties and rheology of polyether-modified poly(acrylic acid) hydrogels. Int. J. Pharm. (2004) 282(1-2):45-60.
31. BROMBERG L, TEMCHENKO M, HATTON TA: Dually responsive microgels from polyether-modified poly(acrylic acid): swelling and drug loading. Langmuir (2002) 18(12):4944-4952.
32. BROMBERG L, TEMCHENKO M, HATTON TA: Smart microgel studies. Polyelectrolyte and drug-absorbing properties of microgels from polyether-modified poly(acrylic acid). Langmuir (2003) 19(21):8675-8684.
33. BROMBERG L, TEMCHENKO M, MOESER GD, HATTON TA: Thermodynamics of temperature-sensitive polyether-modified poly(acrylic acid) microgels. Langmuir (2004) 20(14):5683-5692.
34. BROMBERG L, TEMCHENKO M, ALAKHOV V, HATTON TA: Kinetics of swelling of polyether-modified poly(acrylic acid) microgels with permanent and degradable cross-links. Langmuir (2005) 21(4):1590-1598.
35. BARREIRO-IGLESIAS R, BROMBERG L, TEMCHENKO M, HATTON TA, CONCHEIRO A, ALVAREZ-LORENZO C: Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers. J. Control. Release (2004) 97(3):537-549.
36. BROMBERG LE, BARR DP: Aggregation phenomena in aqueous solutions of hydrophobically modified polyelectrolytes. A probe solubilization study. Macromolecules (1999) 32(11):3649-3657.
37. BROMBERG L, TEMCHENKO M: Loading of hydrophobic compounds into micellar solutions of hydrophobically modified polyelectrolytes. Langmuir (1999) 15(25):8627-8632.
38. HUIBERS PD, BROMBERG LE, ROBINSON BH, HATTON TA: Reversible gelation in semidilute aqueous solutions of associative polymers: a small-angle neutron scattering study. Macromolecules (1999) 32(15):4889-4894.
39. BROMBERG L: Interactions among proteins and hydrophobically modified polyelectrolytes. J. Pharm. Pharmacol. (2001) 53(4):541-547.
40. FASSBERG J, STELLA VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. (1992) 81:676-684.
41. BROMBERG LE, RON ES: Protein and peptide release from temperature-responsive gels and thermogelling polymer matrices. Adv. Drug Deliv. Rev. (1998) 31(3):197-221.
42. BASF Performance Chemicals. FDA and EPA status. BASF Corporation, North Mount Olive, NJ, USA (1993):234.
43. Final Assessment Report of the Safety of Carbomers 934, -934P, -940, -941 and -962. J. Am. Coll. Toxicol. (1982) 1:109-141.
44. BROMBERG L, ALAKHOV V: Effects of polyether-modified poly(acrylic acid) nucrogels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J. Control. Release (2003) 88(1):11-22.
45. BATRAKOVA EV, LI S, MILLER DW, KABANOV AV: Pluronic P85 increases permeability of a broad Spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. (1999) 16(9):1366-1372.
46. BATRAKOVA EV, LI S, VINOGRADOV SV et al.: Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. (2001) 299(2):483-493.
47. ALAKHOV V, KLINSKI E, LI S et al.: Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B: Biointerfaces (1999) 16:113-134.
48. CLEARY J, BROMBERG L, MAGNER E: Adhesion of polyether-modified poly(acrylic acid) to mucin. Langmuir (2004) 20(22):9755-9762.
49. ALAKHOV V, PIETRZYNSKI G, PATEL K, KABANOV A, BROMBERG L, HATTON TA: Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate. J. Pharm. Pharmacol (2004) 56(10):1233-1241.
50. BERKNOP-SCHNÜRCH A, HOFFER MH, KEFEDJIISKI K: Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin. Drug Deliv. (2004) 1(1):87-98.